GLP-1semaglutidepregnancyglp-1 receptor agonistsmeta-analysis

Meta-analysis of 2.1 million pregnancies finds no detectable GLP-1 harm signal

Authors writing in Med stress the pooled observational data cannot establish safety, citing heterogeneity, residual confounding and few datasets per outcome.

By Maren Holt · Senior Reporter, GLP-1

Sep 28 20:00 ETSource: Med (New York, N.Y.)

The wire

01Ten observational studies covering 2,118,215 women, 8,325 of them exposed to GLP-1 receptor agonists within six months before a positive pregnancy test, showed no clearly detectable rise in miscarriage, congenital anomalies, preterm birth, hypertensive disorders or abnormal fetal growth.
02Clinicians fielding questions from patients who conceived while on semaglutide or tirzepatide now have pooled numbers rather than single-cohort reports to frame counselling.
03A lower pooled estimate for preeclampsia (OR 0.87, 95% CI 0.78-0.98) rested on only two datasets, and the exposure-window sensitivity analysis reused the same four studies as the primary malformation analysis, so it was not independent.

From the source

GLP-1 receptor agonist exposure in the periconceptional period and adverse obstetric outcomes: A systematic review and meta-analysis
Med (New York, N.Y.) · 2026 Sep 29 · D'Antonio F, Flacco ME, Manzoli L et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42810337/